Haleon has been in the news with several notable happenings. Pfizer has stepped out of Haleon by selling its $3.3 billion stake; this effectively dissolved their presence in the consumer healthcare base. Provided with various sector analysts and market predictions, Haleon is trying to regain its foothold after a notable stock dip. Concerns on Haleon's growth potential have led Barclays to downgrade its rating to Equalweight. A glimmer of hope was visible as Goldman Sachs upgraded Haleon's rating based on anticipated growth acceleration. Haleon also announced a new board appointment, Tracy Clarke. Shareholder value has been improved via a strategic share buyback move from Haleon. Certain executives are shown to have bought shares through a dividend reinvestment initiative. Notable names like Berenberg and Barclays adjusted expectations by lowering Haleon's stock price target. Haleon teamed up with Brightseed, perhaps for a strategic move to stabilize the situation. A recent analysis suggests Haleon stocks could be undervalued, presenting a possible buying opportunity. To strengthen its financial position, Haleon continues its share buyback. Notably, Haleon announced plans for a £130M R&D hub aimed at transforming global oral health research. But despite these efforts, Haleon shares are forecasted to face a downturn.
Haleon Stocks News Analytics from Wed, 15 Jan 2025 08:00:00 GMT to Fri, 03 Oct 2025 21:49:13 GMT -
Rating 2
- Innovation -4
- Information 7
- Rumor -6
